Glenmark Pharmaceuticals announced the launch of GLIPIQ® (semaglutide) in India for Type 2 Diabetes Mellitus (T2DM) management. This launch aims to set a new benchmark in affordability for GLP-1 therapy, with weekly treatment starting at just ₹325. The drug, available in pre-filled vials and pens, significantly expands access to advanced diabetes treatment for Indian patients, addressing high cost barriers.
Glenmark Introduces GLIPIQ® for Type 2 Diabetes Management
Glenmark Pharmaceuticals Ltd, a global pharmaceutical company, today announced the domestic launch of GLIPIQ® (semaglutide) in India. This drug is specifically indicated for the management of Type 2 Diabetes Mellitus (T2DM). The launch is positioned to establish a new standard for affordability within the GLP-1 therapy class, thereby expanding access to advanced diabetes treatments for a wider population.
Unprecedented Affordability Benchmark
The key highlight of the launch is the pricing structure, which sets a new benchmark for accessibility. The weekly treatment for GLP-1 therapy will now start at an accessible price point of ₹325. The expected weekly cost of treatment with GLIPIQ® ranges from ₹325 to ₹440, which significantly lowers the cost barrier for initiating GLP-1 therapy in India and provides a more affordable entry point into this class of treatment.
Product Features and Delivery
GLIPIQ® has received approval from the Central Drugs Standard Control Organization (CDSCO) following successful multinational, randomized, comparative, active-controlled, open-label Phase III clinical studies conducted in India. The drug is available in both vial and pre-filled pen formats. The vial-based format offers flexibility for physician-guided dosing, especially in earlier stages of treatment, while the pen format offers a self-dosing convenience for long-term therapy. Both formats provide structured treatment pathways, available in strengths of 2 mg/1.5 mL, 4 mg/3 mL, and 8 mg/3 mL.
Commitment to Patient Support
In addition to the affordability measures, Glenmark is introducing the ‘Sankalp’ patient support program (PSP). This program is designed to support therapy initiations, improve comfort with injectable treatment, and ensure long-term adherence, reflecting Glenmark’s commitment to improving health outcomes through better affordability.
Executive Commentary
Commenting on the launch, Mr. Alok Malik, President and Business Head, India Formulations, Glenmark Pharmaceuticals Ltd., stated that affordability is one of the biggest barriers to initiating advanced diabetes therapy in India. He emphasized that GLIPIQ® is setting a new benchmark in affordability, offering a more affordable option while supporting clinically guided initiation and flexible dosing. He also highlighted the support provided by the existing GLP-1 category offering, Liraglutide, and the companion ‘Sankalp’ program.
About Semaglutide and Glenmark
Semaglutide is a GLP-1 receptor agonist widely used in managing Type 2 Diabetes patients, especially those with co-morbidities like obesity, established atherosclerotic cardiovascular disease (ASCVD), heart failure with preserved ejection fraction (HFpEF), and chronic kidney disease (CKD).
Glenmark Pharmaceuticals Limited is a global, research-led pharmaceutical company focusing on innovation and accessibility. It maintains a commercial footprint in over 80+ countries, delivering diversified portfolios across branded, innovative, generics, and consumer health products.
Source: BSE
